What are the common side effects of Serputinib/Serpatinib (Ruitu)?

Selpercatinib (Selpercatinib), as a highly selective RET receptor tyrosine kinase inhibitor, has a safety profile that is significantly different from that of early multi-target TKIs. Oncology drug evaluation generally believes that the side effects of the drug are generally "target-related, highly predictable, and manageable", which is also an important basis for its long-term use in RET-driven tumors. From the perspective of its mechanism of action, seputinib mainly inhibits the RET pathway and has less impact on non-target kinases such as VEGFR. Therefore, the severe skin toxicity and extensive systemic reactions common in some traditional targeted drugs are relatively reduced.

Some patients with non-small cell lung cancer (NSCLC) and thyroid cancer may experience diarrhea, dry mouth or changes in appetite in the early stages of treatment. Such reactions are usually mild to moderate and can be gradually alleviated through dietary adjustments or symptomatic treatment. Metabolically, seputinib may cause increases in blood pressure or fluctuations in liver enzyme levels, so guidelines generally recommend regular monitoring during treatment. This kind of monitoring is not due to the high incidence of severe toxicity, but to the consideration of long-term drug safety management. Compared with early multi-target tyrosine kinase inhibitors, seputinib has higher selectivity and relatively less interference with non-RET pathways, so the incidence of some skin reactions and extensive systemic side effects has been reduced.

It is worth noting that individual patient differences play an important role in side effects. Some patients experience few significant adverse effects, while others may experience brief discomfort early in treatment. When interpreting the drug, medical websites emphasize the importance of doctor-patient communication and standardized follow-up. By promptly adjusting the dose or dealing with accompanying symptoms, treatment compliance can be improved without affecting the efficacy.

In general, the side effect characteristics of seputinib are more “predictable and manageable”, which is also an important basis for its long-term use in a variety of RET-driven tumors.

Reference:https://en.wikipedia.org/wiki/Selpercatinib